Galapagos NV (GLPG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
88
About the Report
About the Report
Summary
Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines. The company's clinical pipeline include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2 and 3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. It conducts clinical trials for various investigational drugs. The company works in collaboration with pharma companies for its research activities. It has its presence in the Netherlands, Belgium, France and Croatia. Galapagos is headquartered in Mechelen, Belgium.
Galapagos NV (GLPG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Galapagos NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 12
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Galapagos NV, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
ProQR Therapeutics and Galapagos Enter into Research Agreeement 15
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 16
Pharnext Enters into Research Agreement with Galapagos 17
Gilead Sciences Enters into Co-Development Agreement with Galapagos 18
Calchan Enters into Research Partnership with Galapagos 19
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 20
AbbVie Expands its Agreement with Galapagos 21
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 23
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 24
Licensing Agreements 25
Novartis Pharma Enters into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Equity Offering 32
Galapagos Raises USD345 Million in Public Offering of ADS 32
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 34
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 35
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 36
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 37
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 38
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 39
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 44
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD425 Million in Private Placement of Shares 46
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 48
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 49
Galapagos Raises USD74.5 Million in Private Placement of Shares 50
Galapagos Raises USD240 Million in Public Offering of Shares 52
Galapagos to Raise Funds through Private Placement 54
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 55
Galapagos Completes Private Placement Of Shares For USD 2.2 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For USD 70 Million 57
Galapagos Completes Private Placement Of Shares For USD 1.5 Million Upon Exercise Of Warrants 58
Galapagos Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 59
Galapagos Completes Private Placement Of Shares For USD 1.5 Million Upon Exercise Of Warrants 60
Asset Transactions 61
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 61
Acquisition 62
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 62
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 63
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To USD 2.3 Million 65
Galapagos NV-Key Competitors 66
Galapagos NV-Key Employees 67
Galapagos NV-Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Recent Developments 69
Financial Announcements 69
Aug 02, 2018: Productive first half-year at Galapagos 69
Apr 25, 2018: Galapagos reports first quarter 2018 results 70
Oct 26, 2017: Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline 71
Jul 27, 2017: Solid financials support R&D progress 72
Jul 27, 2017: Galapagos: Solid financials support R&D progress 73
Apr 27, 2017: Galapagos reports first quarter 2017 results 74
Feb 23, 2017: Galapagos reports strong financial results and newsflow-rich pipeline 75
Corporate Communications 77
Jan 17, 2017: Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer 77
Product News 78
05/15/2017: Seven abstracts on filgotinib accepted by EULAR 2017 78
Clinical Trials 79
Jul 05, 2017: Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis 79
May 07, 2017: Galapagos presents three posters on filgotinib in Crohn's disease at DDW 2017 80
Apr 29, 2017: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI 81
Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 82
Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 83
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 84
Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 85
Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease 86
Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88
List of Figure
List of Figures
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Galapagos NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 12
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
ProQR Therapeutics and Galapagos Enter into Research Agreeement 15
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 16
Pharnext Enters into Research Agreement with Galapagos 17
Gilead Sciences Enters into Co-Development Agreement with Galapagos 18
Calchan Enters into Research Partnership with Galapagos 19
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 20
AbbVie Expands its Agreement with Galapagos 21
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 23
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 24
Novartis Pharma Enters into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Galapagos Raises USD345 Million in Public Offering of ADS 32
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 34
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 35
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 36
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 37
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 38
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 39
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 44
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD425 Million in Private Placement of Shares 46
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 48
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 49
Galapagos Raises USD74.5 Million in Private Placement of Shares 50
Galapagos Raises USD240 Million in Public Offering of Shares 52
Galapagos to Raise Funds through Private Placement 54
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 55
Galapagos Completes Private Placement Of Shares For USD 2.2 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For USD 70 Million 57
Galapagos Completes Private Placement Of Shares For USD 1.5 Million Upon Exercise Of Warrants 58
Galapagos Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 59
Galapagos Completes Private Placement Of Shares For USD 1.5 Million Upon Exercise Of Warrants 60
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 61
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 62
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 63
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To USD 2.3 Million 65
Galapagos NV, Key Competitors 66
Galapagos NV, Key Employees 67
Galapagos NV, Subsidiaries 68
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.